PEP-MOTS-C • RESEARCH USE ONLY

MOTS-C

MOTS-C is a mitochondria-derived peptide that optimizes cellular energy production, glucose metabolism, and metabolic flexibility. This nasal formulation is designed for daily metabolic support, energy enhancement, and longevity signaling through consistent mitochondrial activation.

20 mg

Per Bottle

— 125 mcg per spray

>99%

Purity

— Third-party verified

160

Sprays per bottle

Protocol & Dosing

Use once or twice daily. For optimal metabolic and insulin-sensitizing benefits, take MOTS-C in a fasted state and wait 30–60 minutes before eating. - For fat loss and metabolic support → morning dosing is ideal - For energy and athletic performance → an additional pre-workout dose may be used - Safe for ongoing use but taking 1 week off every 8–12 weeks is recommended to maintain optimal receptor sensitivity.

Starting

250 mcg (2 sprays)

Medium

500 mcg (4 sprays)

Higher

750 mcg (6 sprays)

Cycles

May be used continuously for 8–12 weeks
Take 1-2 weeks off every 8–12 weeks to preserve receptor sensitivity
A very reasonable structure:
MOTS-C: 8–12 weeks
SS-31: 4–6 weeks
Then 2–4 weeks fully off both

Key Benefits

Increases stamina and energy, enhances insulin sensitivity, supports glucose utilization, reduces fatigue, promotes metabolic efficiency, and supports healthy aging and longevity pathways.

Guidance

Start with 2 sprays once daily
Increase gradually only if needed
Maximum typical use: 6 sprays per day
Maintain fasted dosing for best results
Ideal for metabolic optimization, fat loss, energy, and longevity support
Non-stimulatory and well tolerated
Pairs well with NAD+, SS-31, and Humanin for comprehensive mitochondrial support

PROPRIETARY DELIVERY TECHNOLOGY

Protixa ION System™

Nasal delivery is facilitated with the Protixa ION System — a proprietary liquid ion delivery platform engineered for enhanced bioavailability, deep tissue penetration, and improved compound stability without compromising safety. Unlike carriers that rely on encapsulation, it enables direct solubilization and optimized partitioning of actives including peptides and coenzymes — no liposomes, no lipid nanoparticles, no emulsifier-dependent payloads. Built from amino acids and endogenous molecules for biocompatibility; scalable across routes that include intranasal sprays.

Lipid disruption & cation exchange

Alkyl chains intercalate into the stratum corneum lipid matrix via hydrophobic interactions, reducing cohesion and increasing permeability. Cationic components displace native ions such as Ca²⁺ within lipid lamellae, weakening structural integrity so actives pass through more efficiently.

Dual-polarity solubilization

Hydrophilic and lipophilic character solubilizes and transports a broad range of actives directly — without emulsifiers or encapsulating carriers.

Keratin modulation & partitioning

Temporarily denatures keratin within corneocytes, opening transient micro-pathways for epithelial migration. Improves solubility and skin partitioning while maintaining proprietary differentiation for IP — inspired by systems like CAGE (choline–geranic acid ionic liquids).

Superior loading vs. lipid carriers

Solubilizes actives directly instead of inefficient encapsulation. In-house studies: lipid-based carriers penetrated only ~22 μm — insufficient for meaningful absorption — whereas the Protixa ION System reaches therapeutically relevant layers.

>57× vs. saline · <10 nm (DLS)

>57× barrier penetration vs. saline in an ex vivo epithelial model (Protixa third-party data). Minimum confirmed nanoparticle size under 10 nm — mucus-penetrating ionic clusters by dynamic light scattering.

Safety, stability & distribution

ISO 10993-5 CCK-8 assay: 80–100% viability at 24 h and 48 h. Four-month room-temperature stability: 101.1–101.9% HPLC recovery — no cold chain. In vivo oral mouse study: systemic distribution across five organs at 1 hour post-dose.

Compliance · Nasal peptides

cGMP manufacturing & cryopreservation

Manufactured through Pacific Manufacturing & Design LLC — GMP-certified under NSF/ANSI 455-2 and FDA-registered (Reg. No. 15492349536). Compliant with 21 CFR Parts 11, 111, and 117. Strict quality control, validated processes, and full traceability from raw material to final product.

NSF/ANSI 455-2FDA REGISTERED21 CFR PART 11121 CFR PART 117

Third-Party COA — Every Batch

Third-party COA for every batch, ensuring consistent quality and purity. Verified through LCMS and endotoxin testing, with full traceability from raw material to final product.

LCMS CONFIRMED>99% PURITYENDOTOXIN TESTEDAXISPHARM COA